N/A N=3,017 A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Prostatic Neoplasms
Primary: Duration of NHT Treatment — 11.9 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=61 CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Prostate Cancer
Primary: Prostate-Specific Antigen (PSA) or Radiographic Progression — 10 participants
Phase 2 N=119 A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Prostate Cancer
Primary: Percentage of Participants With Total Serum PSA Response — 29; 32; 11; 21 % of responders
Phase 2 N=180 EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
Prostate Cancer Metastatic
Primary: Progression Free Survival (PFS) Time — 3.3; 3.4; 4.3 months
Phase 2 N=63 Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Prostate Cancer Metastatic
Primary: Percentage of Participants With PSA Response — 39.7; 15.9; 55.6 percentage of participants
Phase 3 N=1,088 Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 34.66; 30.29 Months
Phase 2 N=26 Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
Castration Resistant Prostatic Cancer · Metastatic Prostate Cancer
Primary: Radiographic Progression-Free Survival Rate (rPFS) at 6 Months — 0.513; 0.63 proportion of participants
N/A N=2,313 A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
Prostatic Neoplasms
Primary: Duration of Therapy (DOT) — 18.5 Months
Phase 3 N=1,150 A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Metastatic Hormone Sensitive Prostate Cancer
Primary: Radiographic Progression-Free Survival (rPFS) Based on Independent Central Review (ICR) of Bone Scan According to Prostate Cancer Clinical Trials Working Group 2 (PCWG2)…
Phase 2 N=8 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Participants With PSA50 Response — 2 Participants
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Phase 2 N=41 Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer
Prostate Cancer
Primary: Metabolic Syndrome — 0; 0 kilograms
Phase 2 N=41 Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Composite Time to Disease Progression (cTTP) for Participants Treated With Cixutumumab — 4.9; 3.2 months
Phase 2 N=9 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
Metastatic Castration-resistant Prostate Cancer
Primary: Changes in 18F-fluciclovine PET Scan for Patients With mCRPC on Treatment With Life Prolonging Therapies — 5; 0; 3; 0 Participants
Phase 1 N=6 Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
Prostatic Neoplasms · Prostatic Cancer
Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0 Participants
N/A N=2,731 A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant
Primary: Overall Survival (OS): Adjusted Using Inverse Probability Treatment Weighting (IPTW) — 24.63; 25.77 Months — p==0.0088
Phase 2 N=44 Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
Primary: Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR]) — 6.8 percentage of participants
Phase 3 N=1,028 Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Prostate Cancer · Castration Resistant Prostate Cancer · Pain
Primary: Overall Survival (OS) — 11.0; 9.8 months — p=0.213
Phase 2 N=17 A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Prostate Cancer
Primary: Clinical Benefit Rate From Cabozantinib (XL184) — 10 Participants
Phase 2 N=74 Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
Prostate Cancer · Prostate Neoplasms · Neoplasms, Prostatic
Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale
Phase 1 N=17 A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
Prostate Cancer
Primary: Frequency of Dose-limiting Toxicity at Escalating Dose Levels of CTT1403 — 0; 0; 0; 0 Participants
Phase 1 N=27 A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
Prostate Cancer · Hormone Refractory Prostate Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 0; 6; 14; 8 Participants
Phase 3 N=1,251 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
Metastatic Hormone-Sensitive Prostate Cancer
Primary: Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as…
Phase 2 N=20 Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Metastatic Castrate-resistant Prostate Cancer · mCRPC
Primary: Time to Progression — 11.2 weeks
Phase 2 N=46 Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
Prostatic Neoplasms
Primary: Time to Prostate-specific Antigen (PSA) Progression — 7.3 Months
Phase 3 N=1,030 Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
Prostatic Neoplasms
Primary: Overall Survival (OS) — 19.6; 19.0 Months — p=0.1677
Phase 2 N=9 Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
Metastatic Castration-Resistant Prostate Cancer
Primary: Median Time on Treatment — 11 weeks
Phase 2 N=38 Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE) or Serious Adverse Events (SAE) — 6; 8; 23; 5 participants
Phase 2 N=21 A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
Prostate Cancer · Metastatic Castrate Resistant Prostate Cancer
Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 Given Every Two Weeks. — 20 mg/kg every 2 weeks
Phase 2 N=14 Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma
Primary: Proportion of Patients With PSA Decline by 50% From Baseline — 9; 5 Participants